Literature DB >> 27693170

Preclinical study investigating the potential of low-dose-rate brachytherapy with 32P stents for the prevention of restenosis of paranasal neo-ostia.

Elmar Oestreicher1, Harald Bartsch2, Doris Mayr2, Mario Schubert3, Barbara Weber1, Peter Kneschaurek4, Walter Assmann3, Ronald Sroka5, Christian Stephan Betz6.   

Abstract

PURPOSE: Ostial restenosis is a common cause of failures in paranasal sinus surgery. The aim of the current study was to investigate the use of low-dose-rate brachytherapy to prevent neo-ostial restenosis in an animal model. METHODS AND MATERIALS: In 14 rabbits, maxillary neo-ostia were created and measured. One side each was stented with a regular silicone stent, the other side was either not stented (n = 7) or stented with a phosphorous-32 implanted stent depositing a low-dose radiation of 15 Gy (n = 7) within 1 week, after which all stents were removed. After a period of additional 12 weeks of recovery, the animals were sacrificed, the neo-ostia were again measured, and the areas and histopathologic changes compared in between the groups.
RESULTS: After 15-Gy stenting, the mean ostial areas were even slightly enlarged by 5.1% compared to the area at stent removal, whereas a significant reduction in area, indicating a process of restenosis, by 56.1% or 54.0% was seen in the control groups with no stent and normal stent, respectively. Furthermore, no indication for adverse histopathologic radiation effects was seen in the 15-Gy group.
CONCLUSIONS: Low-dose-rate brachytherapy with phosphorous-32 doped silicone stents showed promising results in the prevention of neo-ostium restenosis in this proof-of-concept study, indicating that further preclinical and clinical testing may be warranted.
Copyright © 2016 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Low-dose brachytherapy; Neo-ostium; Paranasal sinus; Phosphorous-32; Restenosis

Mesh:

Substances:

Year:  2016        PMID: 27693170     DOI: 10.1016/j.brachy.2016.08.011

Source DB:  PubMed          Journal:  Brachytherapy        ISSN: 1538-4721            Impact factor:   2.362


  2 in total

1.  Novel Application of 32P Brachytherapy: Treatment of Angiolymphoid Hyperplasia with Eosinophilia in the Right Auricle with 8-Year Follow-Up.

Authors:  Jinshan Zhang; Yuan Li; Ge Wen; Yongmei Deng; Hongxia Yao
Journal:  Cancer Biother Radiopharm       Date:  2018-06-29       Impact factor: 3.099

2.  Development and pre-clinical test of a phosphorous-32 containing polyetheretherketone foil aiming at urethral stricture prevention by low-dose-rate brachytherapy.

Authors:  Walter Assmann; Ricarda Becker; Christian Stief; Ronald Sroka
Journal:  J Contemp Brachytherapy       Date:  2022-04-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.